Ion channel modulators
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
1. A crystalline form of compound:
wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising X-ray powder diffraction peaks at the following diffraction angles (° 2θ): 12.6±0.2, 15.8±0.2, and 18.6±0.2.
2. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising X-ray powder diffraction peaks at the following diffraction angles (° 2θ): 10.7±0.2, 12.3±0.2, 12.6±0.2, 15.8±0.2, 18.6±0.2, and 22.6±0.2.
3. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising X-ray powder diffraction peaks at the following diffraction angles (° 2θ): 10.7±0.2, 12.3±0.2, 12.6±0.2, 14.9±0.2, 15.8±0.2, 16.6±0.2, 16.8±0.2, 18.6±0.2, 21.0±0.2 and 22.6±0.2.
4. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially the same as shown in FIG. 5 A .
5. The crystalline form of claim 1 , wherein the crystalline form has a melting point onset as determined by differential scanning calorimetry at about 107° C.
6. The crystalline form of claim 1 , wherein the crystalline form has a differential scanning calorimetry curve substantially the same as shown in FIG. 5 B .
7. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern is obtained using Cu Kα radiation.
8. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising the crystalline form of claim 2 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the crystalline form of claim 3 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising the crystalline form of claim 4 and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising the crystalline form of claim 5 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising the crystalline form of claim 6 and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising the crystalline form of claim 7 and a pharmaceutically acceptable carrier.